BR112022024294A2 - Bioconjugado shigella-tetravalente (shigella4v)". - Google Patents
Bioconjugado shigella-tetravalente (shigella4v)".Info
- Publication number
- BR112022024294A2 BR112022024294A2 BR112022024294A BR112022024294A BR112022024294A2 BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2 BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2
- Authority
- BR
- Brazil
- Prior art keywords
- shigella
- shigella4v
- bioconjugate
- tetravalent
- composition
- Prior art date
Links
- 241000607768 Shigella Species 0.000 abstract 3
- 241000607762 Shigella flexneri Species 0.000 abstract 1
- 241000607760 Shigella sonnei Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940115939 shigella sonnei Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040844P | 2020-06-18 | 2020-06-18 | |
| US202063043883P | 2020-06-25 | 2020-06-25 | |
| EP20182139 | 2020-06-25 | ||
| EP20182138 | 2020-06-25 | ||
| PCT/IB2021/055361 WO2021255684A1 (en) | 2020-06-18 | 2021-06-17 | Shigella-tetravalent (shigella4v) bioconjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024294A2 true BR112022024294A2 (pt) | 2023-02-28 |
Family
ID=76502778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024294A BR112022024294A2 (pt) | 2020-06-18 | 2021-06-17 | Bioconjugado shigella-tetravalente (shigella4v)". |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230346902A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4168040A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023530154A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697396A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022024294A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3185719A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016587A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021255684A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026087718A1 (en) * | 2024-10-23 | 2026-04-30 | Institut Pasteur | A multivalent shigella vaccine and methods of making and using thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| ES2535084T3 (es) | 2005-05-11 | 2015-05-05 | Eth Zurich | Proteínas N-glicosiladas recombinantes procedentes de células procariotas |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| US9238830B2 (en) | 2006-12-13 | 2016-01-19 | The Governors Of The University Of Alberta | Methods and systems for O-glycosylating proteins |
| SI2257307T1 (sl) | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
| CN101569744A (zh) * | 2009-01-20 | 2009-11-04 | 张鑫 | 一种细菌性痢疾多价疫苗 |
| NO2501406T3 (cg-RX-API-DMAC7.html) | 2009-11-19 | 2018-05-19 | ||
| KR20150068998A (ko) * | 2012-10-12 | 2015-06-22 | 글리코박신 아게 | 숙주 세포 변형 방법 |
| EP2917351B1 (en) * | 2012-11-07 | 2018-12-19 | GlaxoSmithKline Biologicals S.A. | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| NZ723328A (en) | 2014-02-24 | 2018-01-26 | Glycovaxyn Ag | Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture |
| CN106659799B (zh) * | 2014-07-25 | 2020-07-17 | 碧奥辛斯有限责任公司 | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| CN114796472A (zh) * | 2015-06-16 | 2022-07-29 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
-
2021
- 2021-06-17 CA CA3185719A patent/CA3185719A1/en active Pending
- 2021-06-17 WO PCT/IB2021/055361 patent/WO2021255684A1/en not_active Ceased
- 2021-06-17 EP EP21733220.4A patent/EP4168040A1/en active Pending
- 2021-06-17 MX MX2022016587A patent/MX2022016587A/es unknown
- 2021-06-17 US US18/001,551 patent/US20230346902A1/en active Pending
- 2021-06-17 CN CN202180043251.6A patent/CN115697396A/zh active Pending
- 2021-06-17 BR BR112022024294A patent/BR112022024294A2/pt unknown
- 2021-06-17 JP JP2022577503A patent/JP2023530154A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4168040A1 (en) | 2023-04-26 |
| MX2022016587A (es) | 2023-02-01 |
| WO2021255684A1 (en) | 2021-12-23 |
| CN115697396A (zh) | 2023-02-03 |
| CA3185719A1 (en) | 2021-12-23 |
| US20230346902A1 (en) | 2023-11-02 |
| JP2023530154A (ja) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tobe et al. | Activation of motility by sensing short-chain fatty acids via two steps in a flagellar gene regulatory cascade in enterohemorrhagic Escherichia coli | |
| Hoffmann et al. | The Yersinia pseudotuberculosis cytotoxic necrotizing factor (CNFY) selectively activates RhoA | |
| EA202092003A1 (ru) | Соединения для лечения болезни гентингтона | |
| BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
| BR9915852A (pt) | Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina | |
| ES2156199T3 (es) | Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma. | |
| BR112023023671A2 (pt) | Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos | |
| BR0211926A (pt) | agentes para realçar a resposta imune | |
| PE20110023A1 (es) | Composiciones inmunogenicas de antigenos de staphylococcus aureus | |
| CY1118258T1 (el) | Εντεροδιαλυτη συνθεση για την παρασκευη περιβληματος μαλακης καψουλας | |
| DE602006017225D1 (de) | Erbsenproteinzusammensetzung | |
| HK1212249A1 (en) | Bioconjugates comprising modified antigens and uses thereof | |
| BR112022003046A2 (pt) | Conjugados de il-15 e usos dos mesmos | |
| CY1114716T1 (el) | Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες | |
| JOP20230057A1 (ar) | تركيبات لقاح متعددة التكافؤ واستخداماتها | |
| BRPI0409627A (pt) | 2-hidróxi-3-diaminoalcanos de fenacila | |
| Wang et al. | Protein changes in Trichinella spiralis muscle larvae in vitro induced by bovine bile | |
| BR112014015390A8 (pt) | vírus da estomatite vesicular para vacinas iniciais e de reforço | |
| Wang et al. | Protein change of intestinal epithelial cells induced in vitro by Trichinella spiralis infective larvae | |
| NO996514L (no) | Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom | |
| EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
| BR0113915A (pt) | Uso de adenil ciclase da espécie bordetella, composição imunogênica ou farmacêutica, uso da mesma, e , vetor proteináceo | |
| MX2022014249A (es) | Composición farmacéutica para tratar el cáncer. | |
| Wang et al. | Commensals serve as natural barriers to mammalian cells during Acanthamoeba castellanii invasion | |
| MX2022016587A (es) | Bioconjugado tetravalente de shigella (shigella4v). |